Jiangsu Hengrui Pharma 
Welcome,         Profile    Billing    Logout  
 196 Products   52 Diseases   196 Products   3529 Trials   15381 News 


«12...1819202122232425262728...208209»
  • ||||||||||  otesaconazole (VT-1161) / Mycovia Pharma
    Journal:  Sustained Efficacy of Oteseconazole in Women with Recurrent Vulvovaginal Candidiasis. (Pubmed Central) -  Nov 8, 2025   
    The proportion of participants who prematurely discontinued the study was lower in the oteseconazole-treated group (16%) compared with the placebo group (29%). During the 48-week extension study, 1.4% of previously randomized subjects experienced a culture-positive recurrence of symptomatic vulvovaginal candidiasis, demonstrating a continued long-term protective effect of oteseconazole.
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group, Erbitux (cetuximab) / Eli Lilly
    Review, Journal:  Applications and challenges of EGFR inhibitors in the treatment of nasopharyngeal carcinoma. (Pubmed Central) -  Nov 6, 2025   
    The mechanisms of drug resistance are diverse, including primary resistance, secondary mutations, epithelial-mesenchymal transition (EMT), and changes in the tumor microenvironment. This review systematically summarizes the current application status, challenges, and future development prospects of EGFR-targeted therapy, providing a theoretical basis for clinical practice.
  • ||||||||||  thapsigargin / University of Nottingham, Pirbright Institute
    Dual Targeting of KDM1A/LSD1 and Endoplasmic Reticulum Stress Pathways as a Therapeutic Strategy in Glioblastoma (Hawaii Convention Center, Kamehameha Exhibit Hall II & III) -  Nov 5, 2025 - Abstract #WFNOS2025WFNOS_1577;    
    The combinatorial effects of KDM1A knockdown or pharmacological inhibition with NCD38, together with ER stress inducers thapsigargin and brefeldin A, were assessed using cell viability, neurosphere formation, extreme limiting dilution, and apoptosis assays... Our findings demonstrate that KDM1A inhibition induces ER stress in GSCs and targeting KDM1A in combination with ER stress induction represents a promising therapeutic strategy for glioblastoma.
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group
    Phase ? trial on apatinib treating for recurrent or progressive high-grade meningioma (Hawaii Convention Center, Kamehameha Exhibit Hall II & III) -  Nov 5, 2025 - Abstract #WFNOS2025WFNOS_1444;    
    Our preliminary results showed treatment with apatinib achieved prolonged median PFS and OS in patients with recurrent or progressive high-grade meningioma, the related toxicities being manageable. Further investigation involving larger-size cohort is warranted to confirm the the efficacy of apatinib in this patient population.
  • ||||||||||  levetiracetam / Generic mfg.
    Levetiracetam therapeutically targets GABAergic synapses in diffuse midline glioma (Hawaii Convention Center, Kamehameha Exhibit Hall II & III) -  Nov 5, 2025 - Abstract #WFNOS2025WFNOS_1384;    
    P2
    Retrospective real-world clinical data demonstrate longer overall survival for children with DMG who were taking levetiracetam, which was not evident in pediatric hemispheric HGG. These findings uncover growth-promoting GABAergic synaptic communication between GABAergic neurons and DMG cells, underscoring a tumor subtype-specific mechanism of brain cancer neurophysiology with potentially important implications for commonly used drugs in this disease context, which should be further studied in future prospective clinical studies.
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
    Neoadjuvant treatment of recurrent high-grade gliomas with camrelizumab in combination with apatinib: a prospective phase II clinical study (Hawaii Convention Center, Kamehameha Exhibit Hall II & III) -  Nov 5, 2025 - Abstract #WFNOS2025WFNOS_1252;    
    P2
    These findings uncover growth-promoting GABAergic synaptic communication between GABAergic neurons and DMG cells, underscoring a tumor subtype-specific mechanism of brain cancer neurophysiology with potentially important implications for commonly used drugs in this disease context, which should be further studied in future prospective clinical studies. Camrelizumab in combination with apatinib neoadjuvant therapy showed excellent efficacy in recurrent high-grade gliomas, and was significantly superior to PD1 inhibitor monotherapy neoadjuvant treatment in rGBM patients.
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group
    Phase ? trial on apatinib treating for recurrent or progressive high-grade meningioma (Hawaii Convention Center, Kamehameha Exhibit Hall II & III) -  Nov 5, 2025 - Abstract #WFNOS2025WFNOS_949;    
    Our preliminary results showed treatment with apatinib achieved prolonged median PFS and OS in patients with recurrent or progressive high-grade meningioma, the related toxicities being manageable. Further investigation involving larger-size cohort is warranted to confirm the the efficacy of apatinib in this patient population.
  • ||||||||||  Zykadia (ceritinib) / Novartis
    IGF1R inhibition arrests meningioma growth (Hawaii Convention Center, Kamehameha Exhibit Hall II & III) -  Nov 5, 2025 - Abstract #WFNOS2025WFNOS_356;    
    P2
    Ceritinib demonstrated both preclinical efficacy and promising early clinical activity in a case of radiotherapy-resistant recurrent meningioma. To our knowledge, this represents the first report of clinical efficacy of Ceritinib in meningioma.
  • ||||||||||  Nailike (olverembatinib) / Takeda, Hansoh Xinfu (flumatinib) / Jiangsu Hengrui Pharma, Jiangsu Hansoh Pharma
    Clinical features and outcome of Philadelphia chromosome-positive acute lymphoblastic leukemia: A 15-year retrospective study (OCCC - West Halls B3-B4) -  Nov 4, 2025 - Abstract #ASH2025ASH_8215;    
    4.8% of patientsreceived frontline olverembatinib treatment...Patients with ACAs have theworst prognosis compared to those with normal karyotype and Ph alone karyotype, and the impact isless significant under the allogeneic transplantation model. A complex karyotype is an independentunfavorable factor that significantly impacts the prognosis.
  • ||||||||||  Itari (linperlisib) / Shanghai YingLi Pharma
    Efficacy and safety results of linperlisib in adult patients with primary immune thrombocytopenia (ITP) (OCCC - W304EFGH) -  Nov 4, 2025 - Abstract #ASH2025ASH_6189;    
    P1/2
    Linperlisib 40mgQD demonstrated durable, and clinically significant platelet responses in all subgroups with pretreatedITP. A randomized phase 3 study will be continued to further assess the durable clinical benefits oflinperlisib in adult patients with relapsed/refractory ITP.
  • ||||||||||  Doptelet (avatrombopag) / SOBI, Promacta (eltrombopag) / Novartis, Hengqu (hetrombopag) / Jiangsu Hengrui Pharma
    TPO-ras for persistent thrombocytopenia following CAR-T therapy in multiple myeloma: A multicenter clinical experience (OCCC - West Halls B3-B4) -  Nov 4, 2025 - Abstract #ASH2025ASH_5567;    
    A randomized phase 3 study will be continued to further assess the durable clinical benefits oflinperlisib in adult patients with relapsed/refractory ITP. Univariate andmultivariate analyses were conducted between patients with PT (cohort 1) and without PT (cohort 2).Patients with PT were treated with thrombopoietin receptor agonists (TPO-RAs), including: hetrombopag(initial dose: 2.5 mg/day), avatrombopag (initial dose: 20 mg/day), eltrombopag (initial dose: 50 mg/day).Response was defined as transfusion independency along with resolution of platelets > 50
  • ||||||||||  Rituxan (rituximab) / Roche
    Real-world study on thrombopoietin receptor agonists combined with rituximab in the treatment of Relapsed/Refractory primary immune thrombocytopenia (OCCC - West Halls B3-B4) -  Nov 4, 2025 - Abstract #ASH2025ASH_5553;    
    Univariate andmultivariate analyses were conducted between patients with PT (cohort 1) and without PT (cohort 2).Patients with PT were treated with thrombopoietin receptor agonists (TPO-RAs), including: hetrombopag(initial dose: 2.5 mg/day), avatrombopag (initial dose: 20 mg/day), eltrombopag (initial dose: 50 mg/day).Response was defined as transfusion independency along with resolution of platelets > 50 Combination regimens utilized avatrombopag (n=23), eltrombopag (n=32), or hetrombopag (n=33).Rituximab was administered as standard-dose (375 mg/m
  • ||||||||||  Hengqu (hetrombopag) / Jiangsu Hengrui Pharma
    Real-world safety and effectiveness of hetrombopag in patients with primary immune thrombocytopenia (OCCC - West Halls B3-B4) -  Nov 4, 2025 - Abstract #ASH2025ASH_5539;    
    P
    Hetrombopag demonstrated favorable real-world safety and effectiveness in patients withITP, leading to sustained improvements in platelet counts and reduced reliance on concomitanttherapies. These findings provide meaningful evidence supporting the use of hetrombopag in routineclinical practice and underscore its potential as a core component in the long-term management of ITP.
  • ||||||||||  imatinib / Generic mfg.
    Treatment-free remission outcomes in pediatric chronic myeloid leukemia: Second-generation TKIs vs. Imatinib (OCCC - West Halls B3-B4) -  Nov 4, 2025 - Abstract #ASH2025ASH_5102;    
    Background Studies have demonstrated that a subset of adult chronic myeloid leukemia (CML) patients achievingdeep molecular response (DMR) for ?2 years with tyrosine kinase inhibitor (TKI) therapy can successfullydiscontinue treatment and maintain treatment-free remission (TFR), thereby reducing long-term drugtoxicity and financial burden. However, data on TFR in pediatric CML remain limited, particularlyregarding whether second-generation TKIs (e.g.,nilotinib, dasatinib) confer superior TFR rates comparedto first-generation imatinib (IM) in real-world pediatric populations.MethodsThis retrospective multicenter study analyzed clinical data from 54 CML chronic-phase patients aged <18years who discontinued TKI therapy between September 2016 and September 2024 across nine Chinesehematology centers.Patients were stratified into IM and second-generation TKI groups based on pre-discontinuation therapy.Baseline characteristics were compared using Mann-Whitney U and ?
  • ||||||||||  Itari (linperlisib) / Shanghai YingLi Pharma
    PIM1 mutation drives ANXA2 membrane relocalization and promotes lymphomagenesis through PI3K/AKT/mTOR pathway in DLBCL (OCCC - West Halls B3-B4) -  Nov 4, 2025 - Abstract #ASH2025ASH_4517;    
    Additionally, the high-throughput drug screening demonstrated thatthe PIM1L184F mutated cells were more sensitive to the PI3K inhibitor YY20394. PIM1 inhibitor SMI-4acombined with YY20394 showed synergistic antitumor effects both in vitro and in vivo.ConclusionsTaken together, these findings not only shed light on an innovative regulatory mechanismfor how PIM1L184F mutation contributes to the pathogenesis of DLBCL but also provide a potentialtherapeutic strategy for effectively managing DLBCL patients harboring PIM1L184F mutation.
  • ||||||||||  Hansoh Xinfu (flumatinib) / Jiangsu Hengrui Pharma, Jiangsu Hansoh Pharma, Tasigna (nilotinib) / Novartis, Inhibikase
    What is the optimal threshold for aberrant lymphoblasts at diagnosis to predict lymphoid transformation in chronic myeloid leukemia? (OCCC - West Halls B3-B4) -  Nov 4, 2025 - Abstract #ASH2025ASH_3285;    
    Initial TKIs included imatinib (n = 776, 72%),nilotinib (n = 135, 12%), dasatinib (n = 42, 4%), and flumatinib (n = 127, 12%). Low-level ALB detected by FCM at diagnosis in chronic phase patients with CML predictedhigh possibility of subsequent lymphoid transformation during TKI therapy, especially in those with ALB?0.4%.
  • ||||||||||  Review, Journal:  Antibody-Based Therapeutics for Hypercholesterolemia. (Pubmed Central) -  Nov 3, 2025   
    SHR-1918 is another mAb targeting ANGPTL3 being developed in China which may also be effective to treat homozygous FH...Another mAb at an early stage of development is MAR001 targeting angiopoietin-like 4 (ANGPTL4). The role for this remains to be established.
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group, BMS-202 / BMS
    Journal, Checkpoint inhibition:  In Situ Formed Nanocomposite Hydrogel Improve Local Delivery of Antiangiogenic Agents and Immune Checkpoint Inhibitor for Cervical Carcinoma Therapy. (Pubmed Central) -  Nov 3, 2025   
    To address these challenges, a nanocomposite hydrogel system (Apa/BPNPs@Gel) is developed by encapsulating PD-L1 inhibitor BMS202 nanoparticles coated with polyvinyl alcohol (BPNPs) into a polyvinyl alcohol/alginate hybrid hydrogel...Initially, the antiangiogenic agent apatinib (Apa) is released to alleviate tumor hypoxia through vascular normalization and enhance PD-L1 suppression, priming the TME for subsequent anti-PD(L)1 therapy...Notably, in preclinical cervical carcinoma models, Apa/BPNPs@Gel mediated combination therapy significantly inhibited tumor growth and prolonged survival by activating tumor-suppressed CD8+ T cells. Hence, this locally administrable hydrogel offers a versatile platform to modulate the immunosuppressive TME and enhance immunotherapeutic outcomes.